Watch the Cancer: Early Detection video
Cancer: Early Detection
By 2030, cancer cases are expected to have doubled worldwide.
Will you help more people survive cancer through earlier detection?
The most common forms of cancer worldwide are lung, breast, colon, stomach, prostate and liver. For lung, breast and colon cancer, early detection and treatment significantly reduce mortality. However, screening for these cancers through CT scans, mammography and colonoscopy is limited by patient acceptance, side-effects, staff expertise and cost. The reduction in deaths from these cancers due to screening is between 16-24%. Many lives could be saved by an improved test for earlier detection of solid cancers that affect organs.
The world’s first Centre of Excellence for Autoimmunity in Cancer (CEAC) was established at the University in 2011. Our team work with international collaborators and industry to develop blood tests for early detection of cancer. The tests look for antibodies, produced by an individual’s immune system in response to cancer.
Early detection blood tests can detect breast cancer up to four years earlier than a mammogram and can detect lung cancer significantly before patients present with symptoms.
Our research helped launch the world’s first autoantibody test for the early detection of lung cancer, EarlyCDT™-Lung, in the USA in 2010 in collaboration with Oncimmune, a University spin-out company. Initial results have shown the test performs as predicted and it is expected to be launched in the UK by 2012. Building on the success of our blood test for lung cancer, we are working to develop tests for early detection of further cancers, including breast and colon cancer, so treatment can start before the disease has spread.
Our tests will save lives around the world. Early detection of cancer leads to less aggressive treatments, better survival rates and a longer life expectancy. The screening has no side effects and will be more widely accepted by patients. Blood tests are also cheaper and simpler as they don’t call for expert screening staff or specialist equipment.
Early detection of cancer leads to less aggressive treatments, better survival rates and a longer life expectancy. The screening has no side effects and will be more widely accepted by patients. Blood tests are also cheaper and simpler as they don’t call for expert screening staff or specialist equipment.
What will your Impact be?
Your support for Cancer: Early Detection will have a genuine impact on the quality of life of patients in the UK and worldwide and will save more people who might otherwise die from cancer.
University staff sign up to Support Heartlight
Under the Small Change: Big Impact scheme, staff at The University of Nottingham are choosing to round their net pay down to the nearest whole pound, with the pennies collected automatically going to support a Campaign project.
In 2012 staff donations supported HeartLight, with more than £300 per month being directed towards this vital research and helping to save the lives of newborn babies every month.
In 2013 Small Change Big Impact will support the University’s research into the early detection of cancer.
Staff reading this and wishing to sign up should log on to their Intranet Portal and click into the ‘Other Services’ tab.
Bowel cancer is curable by a simple operation when detected early. Despite this, many patients present with late-stage bowel cancer because of the embarrassment associated with current screening tests and the fact that symptoms are non-specific. Screening tests involving stool samples or an invasive internal examination have compliance rates of less than 50%. The advent of a simple blood test represents an exciting opportunity to revolutionise bowel cancer screening and cure more patients.
John Scholefield, Professor of Surgery, Consultant General and Colorectal Surgeon
I believe the technology CEAC is working on has the potential to change the current paradigm of screening and early diagnosis to an initial blood-based test, with subsequent confirmation of cancer by more interventional tests. The potential future opportunities to use the technology in selecting patients for prevention therapies is novel and particularly exciting. It continues to build on the great strength of The University of Nottingham in many aspects of immunology.
Professor Peter Boyle, Scientific Research Committee, Centre of Excellence for Autoimmunity in Cancer (CEAC).
The formation of CEAC by the University is an endorsement of the science we have pursued over the last 15 years. It has resulted in the first blood autoantibody test for the early detection of (lung) cancer. I believe the autoantibody technology will lead to earlier detection of most solid cancers as well as help stratify patients for specific anti-cancer treatments.
Professor John Robertson, Director of CEAC